<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918032</url>
  </required_header>
  <id_info>
    <org_study_id>TRICVD1315</org_study_id>
    <nct_id>NCT02918032</nct_id>
  </id_info>
  <brief_title>International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases</brief_title>
  <official_title>International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to understand the state of onset of NLSD(neutral lipid storage disease) /
      TGCV(triglyceride deposit cardiovasculopathy) worldwide, background information of affected
      patients, and natural history of the disease, as well as exploring the prognostic factors and
      assessing the efficacy of disease-specific treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since NLSD is a rare disease, its clinical manifestation and clinical course have not been
      sufficiently clarified. Also, the number of patients in each country is limited. As such, it
      is considered difficult to fully investigate this disease without international
      collaboration. Therefore, we have established the International Registry of NLSD / TGCV.
      Also, all patients with Jordans' anomaly of peripheral polymorphonuclear leukocytes are
      established as the subjects of entry when starting the registry, to allow entry of patients
      with NLSD due to genes other than mutations of ATGL and CGI-58 genes.

      Time Perspective:This study is both Prospective (registering patients who are diagnosed with
      NLSD / TGCV) and Retrospective (registering only the medical record of previous patients).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Period from the onset of symptoms of NLSD / TGCV to death from any cause</measure>
    <time_frame>5 years</time_frame>
    <description>This is the period from the date of onset of symptoms of NLSD / TGCV to the date of death from any cause. The last date of confirmation of survival will be used as the cut-off date for living patients and patients who are lost to follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum CK(Creatine Kinase) level</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating the serum CK level by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BNP(B-type Natriuretic Peptide) level</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating serum BNP level by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AST(Aspartate transaminase) level</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating serum AST level by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ALT(Alanine transaminase) level</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating serum ALT level by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TG level</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating serum TG level by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose level</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating plasma glucose level by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating HbA1c by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSH(thyroid-stimulating hormone)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating TSH by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free T4</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating Free T4 by measuring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ichthyosis</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of Ichthyosis within 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Jordans' anomaly</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of Jordans' anomaly within 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurosensory disorders</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of neurosensory disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental retardation</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of mental retardation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hearing loss</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of hearing loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle (Musculoskeletal symptoms)</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of musculoskeletal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle (Muscle weakness)</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of muscle weakness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating activities of daily living by Barthel Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical findings of Heart</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of cardiac symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical findings of Liver</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of hepatomegaly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical findings of Pancreas</measure>
    <time_frame>5 years</time_frame>
    <description>Presence / Absence of diabetes mellitus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual muscle test</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating muscles by Manual muscle test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle biopsy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial biopsy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin biopsy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function test</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating muscles by Respiratory function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating heart function by 6-minute ï½—alk distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treadmill endurance time</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating heart function by treadmill endurance time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise test</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating heart function by cardiopulmonary exercise test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle(CT)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating skeletal muscle using CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle(MRI)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating skeletal muscle using MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle(electromyogram)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating skeletal muscle using electromyogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty liver(ultrasonography)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating fatty liver by ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid(ultrasonography)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluating thyroid by ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>5 years</time_frame>
    <description>Measuring echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac CT</measure>
    <time_frame>5 years</time_frame>
    <description>Measuring cardiac CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI</measure>
    <time_frame>5 years</time_frame>
    <description>Measuring cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary angiography</measure>
    <time_frame>5 years</time_frame>
    <description>Measuring coronary angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>5 years</time_frame>
    <description>Measuring electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holter monitoring</measure>
    <time_frame>5 years</time_frame>
    <description>Measuring holter monitoring</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neutral Lipid Storage Disease</condition>
  <arm_group>
    <arm_group_label>NLSD / TGCV</arm_group_label>
    <description>Patients who are diagnosed with NLSD / TGCV</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are diagnosed with NLSD / TGCV with Jordans' anomaly of peripheral
        polymorphonuclear leukocytes before December 31, 2018 (including patients under 20 years of
        age).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are diagnosed with NLSD / TGCV before December31, 2018

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenichi Hirano, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular Medicine, Faculty of Internal Medicine, Graduate School of Osaka University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenichi Hirano, MD, Ph.D</last_name>
    <phone>+81-6-6872-8215</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean M Wu</last_name>
      <phone>650-723-2300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore DiMauro</last_name>
      <phone>212-854-1754</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Zechner</last_name>
      <phone>+43-316-380-0</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Yuan</last_name>
      <phone>+86-66551122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PitiÃ©-SalpÃªtriÃ¨re Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal LaforÃªt</last_name>
      <phone>+33-1-42-16-00-00</phone>
    </contact>
    <contact_backup>
      <last_name>Karim Wahbi</last_name>
      <phone>+33-1-42-16-00-00</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians University</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Reilich</last_name>
      <phone>+49-89-2180-0</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Arca</last_name>
      <phone>+39-6-49911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.C.O. San Filippo Neri Hospital</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00193</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena M Pennisi, MD, Ph.D.</last_name>
      <phone>+39-6-33061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic University</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Tavian, MD</last_name>
      <phone>+39-2-72341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado Angelini</last_name>
      <phone>+39-49-827-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Graduate School of Osaka University</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka-prefecture</state>
        <zip>565-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichi Hirano, MD, Ph.D.</last_name>
      <phone>+81-6-6872-8215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Kodaira-city</city>
        <state>Tokyo</state>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ichizo Nishino</last_name>
      <phone>+81-42-341-2711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6211</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthijs Hesselink</last_name>
      <phone>+31-43-388-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harefield Hospital</name>
      <address>
        <city>Harefield</city>
        <state>London</state>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Banner</last_name>
      <phone>+44-1895-823-737</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Castle University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 7RU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Horvath</last_name>
      <phone>+44-191-208-6000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Jordans anomaly</keyword>
  <keyword>neutral lipid storage disease</keyword>
  <keyword>triglyceride deposit cardiovasculopathy</keyword>
  <keyword>ATGL gene</keyword>
  <keyword>CGI-58 gene</keyword>
  <keyword>primary triglyceride deposit cardiomyovasculopathy (TGCV)</keyword>
  <keyword>neutral lipid storage disease with myopathy (NLSD-M)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
    <mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Ichthyosiform Erythroderma, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

